These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8738054)

  • 1. Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
    Hansen BJ; Flyger H; Mortensen S; Mensink HJ; Meyhoff HH
    Scand J Urol Nephrol; 1996 Apr; 30(2):103-7. PubMed ID: 8738054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group.
    Hansen BJ; Mortensen S; Mensink HJ; Flyger H; Riehmann M; Hendolin N; Nordling J; Hald T
    Br J Urol; 1998 Jan; 81(1):36-41. PubMed ID: 9467474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia.
    Hansen BJ; Flyger H; Brasso K; Schou J; Nordling J; Thorup Andersen J; Mortensen S; Meyhoff HH; Walter S; Hald T
    Br J Urol; 1995 Oct; 76(4):451-8. PubMed ID: 7551880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new patient weighted symptom score system (DAN-PSS-1). Clinical assessment of indications and outcomes of transurethral prostatectomy for uncomplicated benign prostatic hyperplasia.
    Meyhoff HH; Hald T; Nordling J; Andersen JT; Bilde T; Walter S
    Scand J Urol Nephrol; 1993; 27(4):493-9. PubMed ID: 7512748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The symptomatic outcome of transurethral prostatectomy evaluated with the DAN-PSS-1 score system.
    Flyger HL; Holm NR; Nielsen R; Mortensen S
    Scand J Urol Nephrol; 1996 Feb; 30(1):45-9. PubMed ID: 8727865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benign prostatic hyperplasia. Practical treatment guidelines.
    Tammela T
    Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of the Danish Prostate Symptom Score compared to the AUA symptom score and pressure/flow studies in the preoperative evaluation of men with symptomatic benign prostatic hyperplasia.
    Pannek J; Berges RR; Haupt G; Senge T
    Neurourol Urodyn; 1998; 17(1):9-18. PubMed ID: 9453687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision of a patient-weighted symptom score in prostatism. The DAN-PSS-1 questionnaire.
    Brasso K; Stigsby B; Pilsgård B; Nordling J
    Scand J Urol Nephrol; 1994 Mar; 28(1):71-5. PubMed ID: 7516575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
    Lukacs B; Grange JC; Comet D
    Urology; 2000 Apr; 55(4):540-6. PubMed ID: 10736498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
    Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
    Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microwave thermotherapy for benign prostatic hyperplasia.
    Hoffman RM; Monga M; Elliot SP; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004135. PubMed ID: 17943811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
    Bulut S; Ozden C; Aktas BK; Deren T; Tagci S; Gokkaya CS; Baykam MM; Memis A
    Urol Int; 2015; 94(2):181-6. PubMed ID: 25139617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial.
    Djavan B; Shariat S; Fakhari M; Ghawidel K; Seitz C; Partin AW; Roehrborn CG; Marberger M
    Urology; 1999 Feb; 53(2):251-9. PubMed ID: 9933035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
    Wilde MI; Fitton A; McTavish D
    Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of contact laser versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia with small or moderately enlarged prostates.
    Tuhkanen K; Heino A; Aaltomaa S; Ala-Opas M
    Scand J Urol Nephrol; 2003; 37(6):487-93. PubMed ID: 14675922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporary intraurethral prostatic bridge-catheter compared with neoadjuvant and adjuvant alpha-blockade to improve early results of high-energy transurethral microwave thermotherapy.
    Djavan B; Ghawidel K; Basharkhah A; Hruby S; Bursa B; Marberger M
    Urology; 1999 Jul; 54(1):73-80. PubMed ID: 10414730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.